Knee osteoarthritis, osteoporosis Knee OA
Conditions
Interventions
Arm A: Weekly treatment of teriparatide (56.5 micro g) for 24 months.
Arm B: Daily treatment f Vitamin D3 analog 0.25, 0.5, 0.75 or 1.0 micro g) for 24 months.
Sponsors
Matsuda Shuichi
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Patient who was diagnosed as osteoporosis with high risk of fracture Patient who was diagnosed as osteoarthritis of the knee with Kellgren-Lawrence grade 2 or 3. Patient who has knee pain.
Exclusion criteria
Exclusion criteria: Patient who uses corticosteroid The reason of the pain is other than osteoarthritis Patient with dementia Patient who has contraindication for the drug which is used in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease progression by X ray (bone trabecular integrity, Joint space narrowing, width) | — |
Secondary
| Measure | Time frame |
|---|---|
| Cartilage volume by MRI, Grade of osteoarthritis by Xray (Kellgren-Lawrence grade) Clinical outcomes (WOMAC, KSS) | — |
Contacts
Public ContactKohei Nishitani
Kyoto University Hospital
Outcome results
None listed